Ocrelizumab effects on nerve health and satisfaction in MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how ocrelizumab treatment affects a nerve health marker called neurofilament light chain (NfL) and how satisfied you are with the treatment. It may help doctors understand if this medicine works well for people with multiple sclerosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of multiple sclerosis (MS).
- You must have relapsing or primary progressive MS, as confirmed by specific diagnostic criteria.
- You must be starting ocrelizumab for the first time, and your doctor has decided it is the right treatment for you.
- You cannot be in another study testing other MS medicines.
- You cannot have had prior treatment with rituximab or ublituximab.
- You cannot be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
This study looks at whether Ocrelizumab, an MS medication you may already be taking, can help improve fatigue and thinking problems (like memory and focus) in veterans with MS. It involves checking your energy levels and mental abilities over time.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.